ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Merck Provides Update on Multiple Myeloma Studies of KEYTRUDA? in Combination with Other Therapies
americanpharmaceuticalreview
June 14, 2017Merck has provided an update on two combination studies of KEYTRUDA??(pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment o
Pharma Sources Insight January 2025
